Literature DB >> 15120630

The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.

Dan Lu1, Xenia Jimenez, Larry Witte, Zhenping Zhu.   

Abstract

In recent years a variety of recombinant methods have been developed for efficient production of bispecific antibodies (BsAb) in various formats. Bispecific diabody (bDAb), a 55-60 kDa molecule comprising two non-covalently associated cross-over single chain Fv (scFv) polypeptides, represents one of the most promising as well the most straightforward approaches to BsAb production. Here we constructed a bDAb, using two human scFv, 11F8 and A12, directed against the epidermal growth factor receptor (EGFR) and the insulin-like growth factor receptor (IGFR), respectively, as the building blocks. A total of 8 scFv and diabody constructs were prepared comprising the same two variable heavy (V(H)) and variable light (V(L)) chain domains but arranged in different orientations. V(H)/V(L) orientation, i.e., V(H)-linker-V(L) or V(L)-linker-V(H), showed significant effects on the expression and antigen-binding activity of scFv and monospecific diabody of both 11F8 and A12. Further, only 2 out of the 4 possible V(H)/V(L) orientations/arrangements in bDAb construction yielded active products that retain binding activity to both EGFR and IGFR. Both active bDAb preparations retained their original antigen-binding activity after incubation at 37 degrees C in mouse serum for up to 7 days, indicating excellent stability of the constructs. Taken together, our results underscore the importance of identifying/selecting optimal V(H)/V(L) orientation/arrangement for efficient production of active bDAb.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15120630     DOI: 10.1016/j.bbrc.2004.04.060

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

Review 1.  Dual targeting strategies with bispecific antibodies.

Authors:  Roland E Kontermann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.

Authors:  Ryutaro Asano; Keiko Ikoma; Ippei Shimomura; Shintaro Taki; Takeshi Nakanishi; Mitsuo Umetsu; Izumi Kumagai
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

3.  Comprehensive study of domain rearrangements of single-chain bispecific antibodies to determine the best combination of configurations and microbial host cells.

Authors:  Ryutaro Asano; Yuri Kuroki; Sachiko Honma; Mihoko Akabane; Shunsuke Watanabe; Shinzo Mayuzumi; Shuichi Hiyamuta; Izumi Kumagai; Koji Sode
Journal:  MAbs       Date:  2018-07-09       Impact factor: 5.857

4.  A Strategy for Generating a Broad-Spectrum Monoclonal Antibody and Soluble Single-Chain Variable Fragments against Plant Potyviruses.

Authors:  Han-Lin Liu; Wei-Fang Lin; Wen-Chi Hu; Yung-An Lee; Ya-Chun Chang
Journal:  Appl Environ Microbiol       Date:  2015-07-24       Impact factor: 4.792

5.  Characterization of antibodies in single-chain format against the E7 oncoprotein of the human papillomavirus type 16 and their improvement by mutagenesis.

Authors:  Maria Gabriella Donà; Colomba Giorgi; Luisa Accardi
Journal:  BMC Cancer       Date:  2007-01-31       Impact factor: 4.430

6.  Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.

Authors:  Ryutaro Asano; Ippei Shimomura; Shota Konno; Akiko Ito; Yosuke Masakari; Ryota Orimo; Shintaro Taki; Kyoko Arai; Hiromi Ogata; Mai Okada; Shozo Furumoto; Masayoshi Onitsuka; Takeshi Omasa; Hiroki Hayashi; Yu Katayose; Michiaki Unno; Toshio Kudo; Mitsuo Umetsu; Izumi Kumagai
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

Review 7.  The making of bispecific antibodies.

Authors:  Ulrich Brinkmann; Roland E Kontermann
Journal:  MAbs       Date:  2017 Feb/Mar       Impact factor: 5.857

8.  Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer.

Authors:  Hang Zhang; Yuxi Wang; Yangping Wu; Xiaohua Jiang; Yiran Tao; Yuqin Yao; Yujia Peng; Xiangzheng Chen; Yuyin Fu; Lin Yu; Ruixue Wang; Qinhuai Lai; Weirong Lai; Wenting Li; Yuhuan Kang; Shuli Yi; Ying Lu; Lantu Gou; Min Wu; Jinliang Yang
Journal:  Signal Transduct Target Ther       Date:  2017-05-19

9.  A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity.

Authors:  Aruto Sugiyama; Mitsuo Umetsu; Hikaru Nakazawa; Teppei Niide; Tomoko Onodera; Katsuhiro Hosokawa; Shuhei Hattori; Ryutaro Asano; Izumi Kumagai
Journal:  Sci Rep       Date:  2017-06-06       Impact factor: 4.379

10.  Structural considerations for functional anti-EGFR × anti-CD3 bispecific diabodies in light of domain order and binding affinity.

Authors:  Ryutaro Asano; Keisuke Nagai; Koki Makabe; Kento Takahashi; Takashi Kumagai; Hiroko Kawaguchi; Hiromi Ogata; Kyoko Arai; Mitsuo Umetsu; Izumi Kumagai
Journal:  Oncotarget       Date:  2018-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.